Highlights Nicox SA BOERSE MUENCHEN

Equities

NXOA

FR0013018124

Real-time BOERSE MUENCHEN Other stock markets 14:43:25 23/05/2024 BST			5-day change	1st Jan Change
0.369 ^EUR	0.00%		-2.38%	-14.48%

04-22	Nicox: cash position of 9.1 million euros at the end of March	CF
02-28	Nicox, BlackRock Sign Deal for Debt Restructuring	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nicox: cash position of 9.1 million euros at the end of March	04-22	CF
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan	02-08	MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod	01-31	MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA	01-31	CI
Nicox: sales up 29% in 2023	01-25	CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan	12-14	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20/10/23	CI
Nicox Set for Euronext Growth Paris Transfer	26/04/23	MT
Nicox: share price soars, progress on Zerviate in China	14/04/23	CF
Nicox SA Announces New Drug Application Submission for ZERVIATE in China	14/04/23	CI
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	19/03/23	CI
Nicox: cash position reassuring, but sales still limited	18/01/23	CF
Nicox S.A. Reports Net Revenue Results for the Fourth Quarter and Full Year of 2022	18/01/23	CI
Nicox Plans to Move Listing to Euronext Growth Paris	09/01/23	MT
Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma	07/11/22	CI
Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470	31/10/22	CI
Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial	19/09/22	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	16/09/22	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	16/09/22	CI
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology	07/07/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nicox SA BOERSE MUENCHEN

Equities

NXOA

FR0013018124

Highlights

Filters